This article has multiple issues. Please help improve it or discuss these issues on the talk page . (Learn how and when to remove these template messages)
|
Gary L. Johnson | |
---|---|
Citizenship | American |
Occupation | Professor |
Board member of | American Association for Cancer Research (AACR) |
Awards | Kenan Distinguished Professor Hyman L. Battle Distinguished Cancer Research Award |
Academic background | |
Alma mater | California State University, Northridge University of Colorado Medical School University of California, San Francisco |
Academic work | |
Discipline | Pharmacology,Cellular Biology, |
Gary L. Johnson is an American scientist and Professor recognized for his work with oncogenes and stem cells in the fields of molecular pharmacology and cancer cell biology. His other research interests include signaling networks controlling cell function and disease and the behavior of the kinome en masse in cancer. [1]
Johnson is a past Kenan Distinguished Professor,chair of the UNC Chapel Hill Department of Pharmacology,and a member of the UNC Lineberger Comprehensive Cancer Center.
Johnson earned his B.A. in Biology in 1971 at Cal State Northridge,where he graduated Magna Cum Laude,and his Ph.D. in Pharmacology in 1976 at the University of Colorado Medical School. [2] He then completed his PostDoc in 1979 at the University of California,San Francisco. He served as the chair of the Department of Pharmacology at UNC Chapel Hill from 2003 to 2017 and was a Kenan Distinguished Professor from 2011 to 2019. During his time in education,Johnson trained over 80 postdoctoral fellows and PhD students. Now,Johnson works as the co-director of the Program in Molecular Therapeutics for the Lineberger Comprehensive Cancer Center and director of the Human Genome RNAi/CRISPR Screening Facility. [1]
From 1994 to 1999,Johnson served as the Director of Cell Biology for Cadus Pharmaceuticals Inc. He worked four years as a consultant for Atherogenics,Inc. He was a co-founder of KinoDyn,Inc.,a biotech company located in Chapel Hill,NC. [3]
Johnson has made many contributions to the fields of molecular pharmacology and cell biology. In the early 90s,his laboratories demonstrated that oncogenes,such as Ras and Src,activated the MAPK,ERK1/2. This research defined the MAPK signaling network as part a large network of MAP3Ks,MAP2Ks,and MAPKs. They defined the role MAPKs in proliferation,apoptosis,migration,and invasion. [4] His laboratory published 250 MAPK network related papers. His lab was one to demonstrate that agonists targeting the same GPCR have "biased agonism" and "asymmetric signaling." [5] This is when agonists activate signaling pathways at different distinct intensities. In his work with stem cells,they defined a mutation that captured self-renewing tissue stem cell in a permanent state of EMT. [6] The lab has also made advancements in Adaptive Kinome Programming. They defined the adaptive bypass mechanisms that result in the lack of durable responses to targeted kinase inhibitors. [7] Overall,Johnson has over 300 published papers [8]
In 2018,Johnson was awarded the Hyman L. Battle Award for Cancer Research. [1] In 2008,he won a Merit Award from the National Institute of General Medical Sciences. [9]
An oncogene is a gene that has the potential to cause cancer. In tumor cells,these genes are often mutated,or expressed at high levels.
Autocrine signaling is a form of cell signaling in which a cell secretes a hormone or chemical messenger that binds to autocrine receptors on that same cell,leading to changes in the cell. This can be contrasted with paracrine signaling,intracrine signaling,or classical endocrine signaling.
A mitogen-activated protein kinase is a type of protein kinase that is specific to the amino acids serine and threonine. MAPKs are involved in directing cellular responses to a diverse array of stimuli,such as mitogens,osmotic stress,heat shock and proinflammatory cytokines. They regulate cell functions including proliferation,gene expression,differentiation,mitosis,cell survival,and apoptosis.
A mitogen is a small bioactive protein or peptide that induces a cell to begin cell division,or enhances the rate of division (mitosis). Mitogenesis is the induction (triggering) of mitosis,typically via a mitogen. The mechanism of action of a mitogen is that it triggers signal transduction pathways involving mitogen-activated protein kinase (MAPK),leading to mitosis.
The epithelial–mesenchymal transition (EMT) is a process by which epithelial cells lose their cell polarity and cell–cell adhesion,and gain migratory and invasive properties to become mesenchymal stem cells;these are multipotent stromal cells that can differentiate into a variety of cell types. EMT is essential for numerous developmental processes including mesoderm formation and neural tube formation. EMT has also been shown to occur in wound healing,in organ fibrosis and in the initiation of metastasis in cancer progression.
Mitogen Activated Protein (MAP) kinase kinase kinase is a serine/threonine-specific protein kinase which acts upon MAP kinase kinase. Subsequently,MAP kinase kinase activates MAP kinase. Several types of MAPKKK can exist but are mainly characterized by the MAP kinases they activate. MAPKKKs are stimulated by a large range of stimuli,primarily environmental and intracellular stressors. MAPKKK is responsible for various cell functions such as cell proliferation,cell differentiation,and apoptosis. The duration and intensity of signals determine which pathway ensues. Additionally,the use of protein scaffolds helps to place the MAPKKK in close proximity with its substrate to allow for a reaction. Lastly,because MAPKKK is involved in a series of several pathways,it has been used as a therapeutic target for cancer,amyloidosis,and neurodegenerative diseases. In humans,there are at least 19 genes which encode MAP kinase kinase kinases:
Smoothened is a protein that in humans is encoded by the SMO gene. Smoothened is a Class Frizzled G protein-coupled receptor that is a component of the hedgehog signaling pathway and is conserved from flies to humans. It is the molecular target of the natural teratogen cyclopamine. It also is the target of vismodegib,the first hedgehog pathway inhibitor to be approved by the U.S. Food and Drug Administration (FDA).
The MAPK/ERK pathway is a chain of proteins in the cell that communicates a signal from a receptor on the surface of the cell to the DNA in the nucleus of the cell.
In molecular biology,extracellular signal-regulated kinases (ERKs) or classical MAP kinases are widely expressed protein kinase intracellular signalling molecules that are involved in functions including the regulation of meiosis,mitosis,and postmitotic functions in differentiated cells. Many different stimuli,including growth factors,cytokines,virus infection,ligands for heterotrimeric G protein-coupled receptors,transforming agents,and carcinogens,activate the ERK pathway.
p38 mitogen-activated protein kinases are a class of mitogen-activated protein kinases (MAPKs) that are responsive to stress stimuli,such as cytokines,ultraviolet irradiation,heat shock,and osmotic shock,and are involved in cell differentiation,apoptosis and autophagy. Persistent activation of the p38 MAPK pathway in muscle satellite cells due to ageing,impairs muscle regeneration.
RAF kinases are a family of three serine/threonine-specific protein kinases that are related to retroviral oncogenes. The mouse sarcoma virus 3611 contains a RAF kinase-related oncogene that enhances fibrosarcoma induction. RAF is an acronym for Rapidly Accelerated Fibrosarcoma.
The ErbB family of proteins contains four receptor tyrosine kinases,structurally related to the epidermal growth factor receptor (EGFR),its first discovered member. In humans,the family includes Her1,Her2 (ErbB2),Her3 (ErbB3),and Her4 (ErbB4). The gene symbol,ErbB,is derived from the name of a viral oncogene to which these receptors are homologous:erythroblastic leukemia viral oncogene. Insufficient ErbB signaling in humans is associated with the development of neurodegenerative diseases,such as multiple sclerosis and Alzheimer's disease,while excessive ErbB signaling is associated with the development of a wide variety of types of solid tumor.
Mitogen-activated protein kinase 14,also called p38-α,is an enzyme that in humans is encoded by the MAPK14 gene.
ETS Like-1 protein Elk-1 is a protein that in humans is encoded by the ELK1. Elk-1 functions as a transcription activator. It is classified as a ternary complex factor (TCF),a subclass of the ETS family,which is characterized by a common protein domain that regulates DNA binding to target sequences. Elk1 plays important roles in various contexts,including long-term memory formation,drug addiction,Alzheimer's disease,Down syndrome,breast cancer,and depression.
Mitogen-activated protein kinase kinase kinase 3 is an enzyme that in humans is encoded by the MAP3K3 gene,which is located on the long arm of chromosome 17 (17q23.3).
Mitogen-activated protein kinase kinase kinase 1 (MAP3K1) is a signal transduction enzyme that in humans is encoded by the autosomal MAP3K1 gene.
Mitogen-Activated Protein Kinase Kinase Kinase 2 also known as MEKK2 is an enzyme that in humans is encoded by the MAP3K2 gene.
Mitogen-activated protein kinase 4 is an enzyme that in humans is encoded by the MAPK4 gene.
Cédric Blanpain is a Belgian researcher in the field of stem cells. He is a tenured professor of developmental biology and genetics at UniversitéLibre de Bruxelles and director of the stem cell and cancer lab at its Faculty of Medicine. He was one of the first researchers in the world to use cell lineage tracing in cancer research and he showed for the first time the existence of cancer stem cells in solid tumors in vivo. He was selected by Nature as one of 10 People who mattered most in 2012 and he received the outstanding young investigator award of the International Society for Stem Cell Research.
Channing Joseph Der is an American scientist and educator,and Sarah Graham Kenan Distinguished Professor of Pharmacology,at UNC Lineberger Comprehensive Cancer Center. Der is a Fellow of the American Association for the Advancement of Science,He is recognized for his work with the Ras oncoprotein and its role in human oncogenesis.